CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

recombinant covid-19 vaccine (sf9 cells)

Vaccineexperimental

Clinical trial activity

11 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
8
Phase 3
2
Phase 4
0

Earliest trial started Nov 17, 2020 (NCT04640402)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • SARS-CoV-2Immunity, active

    SARS-CoV-2 immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06175494Phase 3Dec 19, 2023Government of China
NCT05770180Phase 2Mar 30, 2023Government of China
NCT05765604Phase 1Mar 14, 2023Government of China
NCT06381843N/AAug 2, 2022Government of China, Sichuan University
NCT05465902Phase 2Jul 31, 2022Government of China
NCT05465785N/AJul 31, 2022Government of China
NCT05463354Phase 2Jul 7, 2022Government of China
NCT05013983Phase 1/Phase 2 (Phase 2)Aug 15, 2021Government of China, Sichuan University
NCT04904471Phase 3Jun 15, 2021Government of China, Sichuan University
NCT04718467Phase 2Feb 1, 2021Government of China, Sichuan University
NCT04640402Phase 2Nov 17, 2020Government of China, Sichuan University
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment111142020
Sichuan UniversityAcademic/Hospital5032020
2 organizations
Page 1 / 1